Your browser doesn't support javascript.
loading
Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
Zheng, Yue; Xue, Yin-Yin; Zhao, Ya-Qin; Chen, Ye; Li, Zhi-Ping.
Affiliation
  • Zheng Y; Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China.
  • Xue YY; Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Zhao YQ; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Chen Y; Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Li ZP; Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Front Immunol ; 14: 1254812, 2023.
Article in En | MEDLINE | ID: mdl-37901233
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Urethral Neoplasms / Immunoconjugates Limits: Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Urethral Neoplasms / Immunoconjugates Limits: Humans Language: En Year: 2023 Type: Article